SG10201508095UA - Humanized Anti-Epiregulin Antibody, And Cancer Therapeutic Agent Comprising Said Antibody As Active Ingredient - Google Patents
Humanized Anti-Epiregulin Antibody, And Cancer Therapeutic Agent Comprising Said Antibody As Active IngredientInfo
- Publication number
- SG10201508095UA SG10201508095UA SG10201508095UA SG10201508095UA SG10201508095UA SG 10201508095U A SG10201508095U A SG 10201508095UA SG 10201508095U A SG10201508095U A SG 10201508095UA SG 10201508095U A SG10201508095U A SG 10201508095UA SG 10201508095U A SG10201508095U A SG 10201508095UA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody
- active ingredient
- therapeutic agent
- humanized anti
- cancer therapeutic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011287654 | 2011-12-28 | ||
| JP2012133394 | 2012-06-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201508095UA true SG10201508095UA (en) | 2015-10-29 |
Family
ID=48697597
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201508095UA SG10201508095UA (en) | 2011-12-28 | 2012-12-28 | Humanized Anti-Epiregulin Antibody, And Cancer Therapeutic Agent Comprising Said Antibody As Active Ingredient |
| SG11201403565XA SG11201403565XA (en) | 2011-12-28 | 2012-12-28 | Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201403565XA SG11201403565XA (en) | 2011-12-28 | 2012-12-28 | Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9556264B2 (es) |
| EP (1) | EP2799543A4 (es) |
| JP (2) | JP6010551B2 (es) |
| KR (1) | KR20140107610A (es) |
| CN (1) | CN104136610B (es) |
| AU (1) | AU2012361510B8 (es) |
| BR (1) | BR112014015581A2 (es) |
| CA (1) | CA2862254A1 (es) |
| CL (1) | CL2014001730A1 (es) |
| CO (1) | CO7101193A2 (es) |
| CR (1) | CR20140352A (es) |
| HK (1) | HK1200187A1 (es) |
| IL (1) | IL233368A0 (es) |
| MX (1) | MX350044B (es) |
| MY (1) | MY172428A (es) |
| PE (1) | PE20141560A1 (es) |
| PH (1) | PH12014501468A1 (es) |
| RU (1) | RU2634383C2 (es) |
| SG (2) | SG10201508095UA (es) |
| TW (1) | TWI593705B (es) |
| UA (1) | UA115046C2 (es) |
| WO (1) | WO2013100120A1 (es) |
| ZA (1) | ZA201405405B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007312367B2 (en) | 2006-10-12 | 2012-09-06 | Chugai Seiyaku Kabushiki Kaisha | Diagnosis and treatment of cancer using anti-EREG antibody |
| EP2436397B1 (en) | 2009-05-29 | 2017-05-10 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition containing antagonist of egf family ligand as component |
| DK2728002T3 (da) | 2011-06-30 | 2022-04-04 | Chugai Pharmaceutical Co Ltd | Heterodimeriseret polypeptid |
| JP6291254B2 (ja) | 2011-10-28 | 2018-03-14 | 中外製薬株式会社 | 癌幹細胞特異的分子 |
| TWI593705B (zh) | 2011-12-28 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient |
| EP2940135B9 (en) | 2012-12-27 | 2021-09-08 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerized polypeptide |
| RU2016101716A (ru) * | 2013-06-24 | 2017-07-27 | Чугаи Сейяку Кабусики Кайся | Терапевтический агент, содержащий гуманизированное антиэпирегулиновое антитело в качестве действующего ингредиента для немелкоклеточной карциномы легкого, за исключением аденокарциномы |
| BR112016014824A2 (pt) * | 2013-12-27 | 2017-09-19 | Chugai Pharmaceutical Co Ltd | Método para purificar anticorpo que tem ponto isoelétrico baixo |
| EA201692109A1 (ru) * | 2014-05-01 | 2017-03-31 | Дженентек, Инк. | Варианты антител к фактору d и их применение |
| WO2016027859A1 (ja) | 2014-08-20 | 2016-02-25 | 中外製薬株式会社 | 蛋白質溶液の粘度測定方法 |
| JP2019202936A (ja) * | 2016-08-17 | 2019-11-28 | 中外製薬株式会社 | 抗Ｅｐｉｒｅｇｕｌｉｎ抗体と抗ＥＧＦＲ抗体との併用医薬 |
| WO2018155611A1 (ja) | 2017-02-24 | 2018-08-30 | 中外製薬株式会社 | 薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法 |
| CN110753703B (zh) * | 2017-05-23 | 2024-04-09 | 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） | 新的cd73抗体、其制备和用途 |
| GB201803892D0 (en) * | 2018-03-12 | 2018-04-25 | Ultrahuman Six Ltd | C-met binding agents |
| JPWO2020045545A1 (ja) | 2018-08-29 | 2021-08-12 | 中外製薬株式会社 | 抗体半分子、および抗体半分子のホモ二量体形成を抑制する方法 |
| EP3915581A4 (en) * | 2019-01-24 | 2023-03-22 | Chugai Seiyaku Kabushiki Kaisha | NOVEL CANCER ANTIGENS AND ANTIBODIES OF THESE ANTIGENS |
| JP7232707B2 (ja) | 2019-05-21 | 2023-03-03 | トーソー株式会社 | ブラケット構造 |
| CN112574308A (zh) | 2019-09-30 | 2021-03-30 | 和铂医药(苏州)有限公司 | 靶向bcma的抗体、双特异性抗体及其用途 |
| CN113150155B (zh) * | 2021-04-22 | 2022-04-08 | 安徽瀚海博兴生物技术有限公司 | 一种抗pd-l1人源化单克隆抗体及其应用 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5190858A (en) | 1989-02-01 | 1993-03-02 | Oncogene Science, Inc. | Monoclonal antibodies directed to epitopes of human transforming growth factor--α and uses thereof |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| WO1993011161A1 (en) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| EP0656941B1 (en) | 1992-03-24 | 2005-06-01 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| JPH07509137A (ja) | 1992-07-24 | 1995-10-12 | セル ジェネシス，インク． | 異種抗体の生産 |
| US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
| EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS |
| US5783417A (en) | 1993-06-04 | 1998-07-21 | Taisho Pharmaceutical Co., Ltd. | Human-derived tumor cell growth inhibitors |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| AU690171B2 (en) | 1993-12-03 | 1998-04-23 | Medical Research Council | Recombinant binding proteins and peptides |
| US5994524A (en) | 1994-07-13 | 1999-11-30 | Chugai Seiyaku Kabushiki Kaisha | Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US6172213B1 (en) | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
| US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| PL343322A1 (en) | 1998-04-03 | 2001-08-13 | Chugai Pharmaceutical Co Ltd | Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody |
| DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
| MXPA01007170A (es) | 1999-01-15 | 2002-07-30 | Genentech Inc | Variantes de polipeptidos con funcion efectora alterada. |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| CN100340575C (zh) | 1999-06-25 | 2007-10-03 | 杰南技术公司 | 人源化抗ErbB2抗体及其在制备药物中的应用 |
| MXPA03002974A (es) | 2000-10-06 | 2004-05-05 | Kyowa Hakko Kogyo Kk | Celulas que producen composiciones de anticuerpo. |
| CU22979A1 (es) | 2000-12-08 | 2004-09-09 | Centro Inmunologia Molecular | Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina |
| US20030003097A1 (en) | 2001-04-02 | 2003-01-02 | Idec Pharmaceutical Corporation | Recombinant antibodies coexpressed with GnTIII |
| JP4063769B2 (ja) | 2001-12-28 | 2008-03-19 | 中外製薬株式会社 | タンパク質安定化方法 |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| AU2003242024A1 (en) | 2002-06-05 | 2003-12-22 | Chugai Seiyaku Kabushiki Kaisha | Method of constructing antibody |
| JP2006512895A (ja) | 2002-06-28 | 2006-04-20 | ドマンティス リミテッド | リガンド |
| WO2004029207A2 (en) | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
| ATE475708T1 (de) * | 2003-01-22 | 2010-08-15 | Glycart Biotechnology Ag | Fusionskonstrukte und deren verwendung zur produktion von antikörpern mit erhöhter fc rezeptor bindungsaffinität und effektorfunktion |
| AU2004220156B2 (en) | 2003-03-14 | 2007-04-19 | Taisho Pharmaceutical Co., Ltd. | Monoclonal antibody and hybridoma producing the same |
| US7195764B2 (en) | 2003-04-14 | 2007-03-27 | Arius Research Inc. | Cancerous disease modifying antibodies |
| HUE039803T2 (hu) | 2004-01-07 | 2019-02-28 | Novartis Vaccines & Diagnostics Inc | M-CSF-specifikus monoklonális ellenanyag és alkalmazásai |
| NL1027975C2 (nl) | 2004-01-09 | 2005-12-23 | Pfizer | Antilichamen tegen MAdCAM. |
| KR101149242B1 (ko) | 2004-01-12 | 2012-05-25 | 어플라이드 몰리큘라 에볼류션, 인코포레이티드 | Ｆｃ 영역 변이체 |
| CA2555145A1 (en) | 2004-02-06 | 2005-08-25 | Wyeth | Diagnosis and therapeutics for cancer |
| EP1776384B1 (en) | 2004-08-04 | 2013-06-05 | Mentrik Biotech, LLC | Variant fc regions |
| JP2008510007A (ja) | 2004-08-16 | 2008-04-03 | メディミューン，インコーポレーテッド | 抗体依存性細胞性細胞傷害活性が増強されたＥｐｈ受容体Ｆｃ変異体 |
| EP1778728A2 (en) | 2004-08-19 | 2007-05-02 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2587766A1 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
| EP2208783A1 (en) | 2004-12-22 | 2010-07-21 | Chugai Seiyaku Kabushiki Kaisha | Method of producing an antibody using a cell in which the function of fucose transporter is inhibited |
| JP2008527978A (ja) | 2005-01-11 | 2008-07-31 | モレキュラー ロジックス，インコーポレイテッド | Ｐａｎ−ＨＥＲアンタゴニストおよび使用方法 |
| WO2006105338A2 (en) | 2005-03-31 | 2006-10-05 | Xencor, Inc. | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
| US8008443B2 (en) | 2005-04-26 | 2011-08-30 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
| JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
| EP2573114B1 (en) | 2005-08-10 | 2016-03-30 | MacroGenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| AU2006299429B2 (en) | 2005-10-03 | 2012-02-23 | Xencor, Inc. | Fc variants with optimized Fc receptor binding properties |
| JP2009525762A (ja) | 2006-02-08 | 2009-07-16 | ターゲッティド・モレキュラー・ダイアグナスティクス・エルエルシー | 二価性ＥｒｂＢリガンド結合分子ならびにその調製および使用のための方法 |
| US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| AU2007312367B2 (en) * | 2006-10-12 | 2012-09-06 | Chugai Seiyaku Kabushiki Kaisha | Diagnosis and treatment of cancer using anti-EREG antibody |
| DK2426143T3 (en) | 2007-01-05 | 2017-09-11 | Univ Zuerich | Process for providing disease-specific binding molecules and targets |
| WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
| MY163473A (en) | 2007-09-26 | 2017-09-15 | Chugai Pharmaceutical Co Ltd | Modified antibody constant region |
| JP2009078946A (ja) | 2007-09-26 | 2009-04-16 | Fujifilm Corp | コア−シェル型金属酸化物粒子及びその製造方法 |
| MY148637A (en) | 2007-09-28 | 2013-05-15 | Chugai Pharmaceutical Co Ltd | Anti-glypican-3 antibody having improved kinetics in plasma |
| EP2436397B1 (en) | 2009-05-29 | 2017-05-10 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition containing antagonist of egf family ligand as component |
| GB0909904D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Product |
| GB0909906D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Antibodies |
| SG196836A1 (en) | 2010-10-06 | 2014-02-13 | Pharmalogicals Res Pte Ltd | Cancer stem cell population and method for production thereof |
| DK2728002T3 (da) * | 2011-06-30 | 2022-04-04 | Chugai Pharmaceutical Co Ltd | Heterodimeriseret polypeptid |
| TWI593705B (zh) | 2011-12-28 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient |
| RU2016101716A (ru) | 2013-06-24 | 2017-07-27 | Чугаи Сейяку Кабусики Кайся | Терапевтический агент, содержащий гуманизированное антиэпирегулиновое антитело в качестве действующего ингредиента для немелкоклеточной карциномы легкого, за исключением аденокарциномы |
-
2012
- 2012-12-26 TW TW101150028A patent/TWI593705B/zh not_active IP Right Cessation
- 2012-12-28 AU AU2012361510A patent/AU2012361510B8/en not_active Ceased
- 2012-12-28 JP JP2013551852A patent/JP6010551B2/ja not_active Expired - Fee Related
- 2012-12-28 WO PCT/JP2012/084042 patent/WO2013100120A1/ja active Application Filing
- 2012-12-28 SG SG10201508095UA patent/SG10201508095UA/en unknown
- 2012-12-28 UA UAA201408353A patent/UA115046C2/uk unknown
- 2012-12-28 MX MX2014008009A patent/MX350044B/es active IP Right Grant
- 2012-12-28 MY MYPI2014701733A patent/MY172428A/en unknown
- 2012-12-28 KR KR20147020786A patent/KR20140107610A/ko not_active Application Discontinuation
- 2012-12-28 CN CN201280070788.2A patent/CN104136610B/zh not_active Expired - Fee Related
- 2012-12-28 CA CA2862254A patent/CA2862254A1/en not_active Abandoned
- 2012-12-28 RU RU2014130766A patent/RU2634383C2/ru not_active IP Right Cessation
- 2012-12-28 PE PE2014001036A patent/PE20141560A1/es not_active Application Discontinuation
- 2012-12-28 EP EP12863154.6A patent/EP2799543A4/en not_active Withdrawn
- 2012-12-28 SG SG11201403565XA patent/SG11201403565XA/en unknown
- 2012-12-28 BR BR112014015581-0A patent/BR112014015581A2/pt not_active IP Right Cessation
- 2012-12-28 US US14/369,539 patent/US9556264B2/en not_active Expired - Fee Related
-
2014
- 2014-06-25 IL IL233368A patent/IL233368A0/en unknown
- 2014-06-25 PH PH12014501468A patent/PH12014501468A1/en unknown
- 2014-06-26 CL CL2014001730A patent/CL2014001730A1/es unknown
- 2014-07-22 CR CR20140352A patent/CR20140352A/es unknown
- 2014-07-22 ZA ZA2014/05405A patent/ZA201405405B/en unknown
- 2014-07-24 CO CO14161083A patent/CO7101193A2/es unknown
-
2015
- 2015-01-16 HK HK15100507.9A patent/HK1200187A1/xx not_active IP Right Cessation
-
2016
- 2016-09-15 US US15/266,829 patent/US20170129950A1/en not_active Abandoned
- 2016-09-16 JP JP2016181435A patent/JP6329601B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1200187A1 (en) | Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient | |
| HK1252481A1 (zh) | 疏水性治療劑的製劑、其製備方法及應用 | |
| HK1203309A1 (en) | Antibody drug conjugates and related compounds, compositions, and methods | |
| IL231386A0 (en) | Pyrazoloquinolinone derivatives, their preparation and medical use | |
| IL228738B (en) | Antibody against cldn6, a pharmaceutical preparation including it and its use | |
| BR112014009634A2 (pt) | preparação e agente terapêutico | |
| SG2014008304A (en) | C10rf32 antibodies, and uses thereof for treatment of cancer | |
| EP2868667A4 (en) | THERAPEUTIC FOR ANEMIA, INCLUDING NICE ENAMA AND CANCER-INDUCED ANEMIA WITH ANTI-BMP9 ANTIBODY AS ACTIVE AGENT | |
| EP2792746A4 (en) | OLIGONUCLEOTIDE AND THERAPEUTIC FOR HYPERLIPIDEMIA WITH THIS AS AN ACTIVE SUBSTANCE | |
| EP2773637A4 (en) | BENZOLSULFONAMIDE COMPOUNDS AND THEIR USE AS MEDICAMENTS | |
| ZA201209145B (en) | Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application | |
| ZA201308186B (en) | Solid, particulate tanning agent preparations | |
| IL227558A0 (en) | A therapeutic agent for tumors | |
| IL231444A0 (en) | Aniline derivatives, their preparation and medical application | |
| PL2729008T3 (pl) | Systemy, sposoby i formulacje do leczenia raka | |
| HK1223567A1 (zh) | 含有人源化抗上皮調節蛋白抗體作爲有效成分的腺癌以外的非小細胞肺癌的治療藥 | |
| HK1215959A1 (zh) | 人源化抗體、其藥劑偶聯物以及它們的用途 | |
| IL233238A0 (en) | Sulphonylaminopyrrolidinone derivatives, their preparation and therapeutic use | |
| IL220859A0 (en) | Alkyl-heterocycle-carbamate derivatives, their preparation and therapeutic application | |
| EP2781521A4 (en) | NOVEL COMPOUND OF SPIROINDOLINE AND THERAPEUTIC AGENT CONTAINING THE SAME | |
| IL232339A0 (en) | 32rf10c antibodies, and their uses for cancer treatment | |
| BR112014005011A2 (pt) | composto, métodos de tratamento e composição farmacêutica |